Top

Published in:

01-04-2013 | Issues in the Nutritional Treatment of Type 2 Diabetes and Obesity (E Mayer-Davis, Section Editor)

Role of Vitamin D in the Development of Insulin Resistance and Type 2 Diabetes

Authors: Stefan Pilz, Katharina Kienreich, Femke Rutters, Renate de Jongh, Adriana J. van Ballegooijen, Martin Grübler, Andreas Tomaschitz, Jacqueline M. Dekker

Published in: Current Diabetes Reports | Issue 2/2013

Abstract

Vitamin D deficiency is mainly a consequence of insufficient sunlight induced vitamin D production in the skin and has been associated with various chronic diseases including type 2 diabetes. Experimental data have shown that vitamin D is important for glucose induced insulin secretion, improves insulin resistance, and exerts anti-inflammatory actions. Epidemiological studies have largely documented that a poor vitamin D status is associated with higher risk of insulin resistance and type 2 diabetes. The majority of randomized controlled trials (RCTs) in healthy or prediabetic individuals have, however, failed to demonstrate relevant vitamin D effects on insulin resistance or diabetes incidence. In patients with type 2 diabetes, a few RCTs reported some moderate effects of vitamin D on glycemic control and insulin resistance. While these findings warrant further in-depth studies, the current evidence is insufficient to recommend vitamin D supplementation for the prevention or treatment of type 2 diabetes.

Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25:585–91.PubMedCrossRef

Badenhoop K, Kahles H, Penna-Martinez M. vitamin d, immune tolerance, and prevention of Type 1 Diabetes. Curr Diab Rep. (in press).

Thomas GN, Scragg R, Jiang CQ, et al. Hyperglycaemia and vitamin D: a systematic overview. Curr Diabetes Rev. 2012;8:18–31.PubMedCrossRef

Muscogiuri G, Sorice GP, Ajjan R, et al. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr Metab Cardiovasc Dis. 2012;22:81–7.PubMedCrossRef

Holick MF. Diabetes and vitamin D connection. Curr Diab Rep. 2008;8:393–8.PubMedCrossRef

Li YC. Vitamin DF, and diabetic nephropathy. Curr Diab Rep. 2008;8:464–9.PubMedCrossRef

Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726–76.PubMedCrossRef

Pilz S, Tomaschitz A, März W, et al. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol. 2011;75:575–84.CrossRef

Pilz S, Tomaschitz A, Drechsler C, et al. Vitamin D supplementation: a promising approach for the prevention and treatment of strokes. Curr Drug Targets. 2011;12:88–96.PubMedCrossRef

10.

Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity, and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9:709–15.PubMedCrossRef

11.

Pilz S, Tomaschitz A, Drechsler C, et al. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res. 2010;54:1103–13.PubMed

12.

• Kupferschmidt K. Uncertain verdict as vitamin D goes on trial. Science. 2012;337:1476–8. This article aims to summarize current controversial views on vitamin D and gives an overview on large ongoing vitamin D trials. PubMedCrossRef

13.

Macdonald HM, Mavroeidi A, Fraser WD, et al. Sunlight and dietary contributions to the seasonal vitamin D status of cohorts of healthy postmenopausal women living at northerly latitudes: a major cause for concern? Osteoporos Int. 2011;22:2461–72.PubMedCrossRef

14.

Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol. 2010;121:297–300.PubMedCrossRef

15.

Autier P, Gandini S, Mullie P. A systematic review: influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. J Clin Endocrinol Metab. 2012;97:2606–13.PubMedCrossRef

16.

Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–64.PubMedCrossRef

17.

Holick MF. Vitamin D, status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73–8.PubMedCrossRef

18.

Peterlik M, Cross HS. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. Eur J Clin Nutr. 2009;63:1377–86.PubMedCrossRef

19.

Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180–8.PubMedCrossRef

20.

Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2010;39:419–46.PubMedCrossRef

21.

Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351385.PubMed

22.

Jorde R, Schirmer H, Wilsgaard T, et al. Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study. PLoS One. 2012;7:e37295.PubMedCrossRef

23.

Wolden-Kirk H, Overbergh L, Christesen HT, et al. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol. 2011;347:106–20.PubMedCrossRef

24.

Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823–5.PubMedCrossRef

25.

Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol. 1999;160:87–95.PubMedCrossRef

26.

Kajikawa M, Ishida H, Fujimoto S, et al. An insulinotropic effect of vitamin D analog with increasing intracellular Ca2+ concentration in pancreatic beta-cells through nongenomic signal transduction. Endocrinology. 1999;140:4706–12.PubMedCrossRef

27.

Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin d in insulin resistance. J Biomed Biotechnol. 2012;2012:634195.PubMed

28.

Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia. 2011;54:2077–81.PubMedCrossRef

29.

Dirks-Naylor AJ, Lennon-Edwards S. The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol. 2011;125:159–68.PubMedCrossRef

30.

Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009;307:77–82.PubMedCrossRef

31.

Bellia A, Marinoni G, D’Adamo M, et al. Parathyroid hormone and insulin resistance in distinct phenotypes of severe obesity: a cross-sectional analysis in middle-aged men and premenopausal women. J Clin Endocrinol Metab. (in press).

32.

Wu YY, Yu T, Zhang XH, et al. 1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling. J Steroid Biochem Mol Biol. 2012;132:112–9.PubMedCrossRef

33.

Prietl B, Pilz S, Wolf M, et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12:136–9.PubMed

34.

Giulietti A, van Etten E, Overbergh L, et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract. 2007;77:47–57.PubMedCrossRef

35.

Geldmeyer-Hilt K, Heine G, Hartmann B, et al. 1,25-dihydroxyvitamin D3 impairs NF-κB activation in human naïve B cells. Biochem Biophys Res Commun. 2011;407:699–702.PubMedCrossRef

36.

Lindqvist PG, Olsson H, Landin-Olsson M. Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study? Diabetes Res Clin Pract. 2010;90:109–14.PubMedCrossRef

37.

Ishii H, Suzuki H, Baba T, et al. Seasonal variation of glycemic control in type 2 diabetic patients. Diabetes Care. 2001;24:1503.PubMedCrossRef

38.

Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29:650–6.PubMedCrossRef

39.

Liu S, Song Y, Ford ES, et al. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28:2926–32.PubMedCrossRef

40.

Fung GJ, Steffen LM, Zhou X, et al. Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study. Am J Clin Nutr. 2012;96:24–9.PubMedCrossRef

41.

Maki KC, Fulgoni 3rd VL, Keast DR, et al. Vitamin d intake and status are associated with lower prevalence of metabolic syndrome in U.S. Adults: national health and nutrition examination surveys 2003–2006. Metab Syndr Relat Disord. 2012;10:363–72.PubMedCrossRef

42.

• Forouhi NG, Ye Z, Rickard AP, et al. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia. 2012;55:2173–82. This paper highlights in 2 original studies and a meta-analysis that low 25-hydroxyvitamin D levels are a risk factor for incident diabetes. PubMedCrossRef

43.

Pittas AG, Nelson J, Mitri J, et al. Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program. Diabetes Care. 2012;35:565–73.PubMedCrossRef

44.

Hartaigh B, Thomas GN, Silbernagel G, et al. Association of 25-hydroxyvitamin D with type 2 diabetes among patients undergoing coronary angiography: cross-sectional findings from the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study. Clin Endocrinol. (in press).

45.

Kabadi SM, Lee BK, Liu L. Joint Effects of obesity and vitamin D insufficiency on insulin resistance and Type 2 Diabetes: results from the NHANES 2001–2006. Diabetes Care. 2012;35:2048–54.PubMedCrossRef

46.

Pilz S, van den Hurk K, Nijpels G, et al. Vitamin D status, incident diabetes and prospective changes in glucose metabolism in older subjects: the Hoorn study. Nutr Metab Cardiovasc Dis. 2012;22:883–9.PubMedCrossRef

47.

Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008;57:2619–25.PubMedCrossRef

48.

Kayaniyil S, Retnakaran R, Harris SB, et al. Prospective associations of vitamin D with β-cell function and glycaemia: the PROspective metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes. 2011;60:2947–53.PubMedCrossRef

49.

Gulseth HL, Gjelstad IM, Tierney AC, et al. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care. 2010;33:923–5.PubMedCrossRef

50.

Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes. 2012;36:387–96.CrossRef

51.

Annuzzi G, Della Pepa G, Vetrani C. Vitamin D and cardiovascular disease: is there evidence to support the bandwagon? Curr Atheroscler Rep. (in press).

52.

• George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med. 2012;29:e142–50. Important recent meta-analysis on randomized controlled trials addressing the effect of vitamin D supplementation on glycemic outcomes and incident diabetes. PubMedCrossRef

53.

• Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65:1005–15. Important recent meta-analysis on observational studies and randomized controlled trials addressing the effect of vitamin D on glycemic outcomes and incident diabetes. PubMedCrossRef

54.

Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009;48:349–54.PubMedCrossRef

55.

Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321–7.PubMedCrossRef

56.

Nilas L, Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes. 1984;8:407–11.PubMed

57.

Ljunghall S, Lind L, Lithell H, et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance–a prospective randomized double-blind study. Acta Med Scand. 1987;222:361–7.PubMedCrossRef

58.

Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994;59:1083–7.PubMed

59.

Fliser D, Stefanski A, Franek E, et al. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest. 1997;27:629–33.PubMedCrossRef

60.

Major GC, Alarie F, Doré J, et al. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85:54–9.PubMed

61.

Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980–6.PubMedCrossRef

62.

Sugden JA, Davies JI, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25:320–5.PubMedCrossRef

63.

de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health Initiative. Diabetes Care. 2008;31:701–7.PubMedCrossRef

64.

Avenell A, Cook JA, MacLennan GS, et al. Vitamin D supplementation and type 2 diabetes: a substudy of a randomized placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2009;38:606–9.PubMedCrossRef

65.

Li X, Liao L, Yan X, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2009;25:411–6.PubMedCrossRef

66.

Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267:462–72.PubMedCrossRef

67.

Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26:19–27.PubMedCrossRef

68.

von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomized, placebo-controlled trial. Br J Nutr. 2010;103:549–55.CrossRef

69.

Witham MD, Dove FJ, Dryburgh M, et al. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomized controlled trial. Diabetologia. 2010;53:2112–9.PubMedCrossRef

70.

de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet. 2010;376:1543–51.PubMedCrossRef

71.

Bock G, Prietl B, Mader JK, et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev. 2011;27:942–5.PubMedCrossRef

72.

Grimnes G, Figenschau Y, Almås B, Jorde R. Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique. Diabetes. 2011;60:2748–57.PubMedCrossRef

73.

Gepner AD, Ramamurthy R, Krueger DC, et al. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One. 2012;7:e36617.PubMedCrossRef

74.

Wood AD, Secombes KR, Thies F, et al. Vitamin D3 Supplementation has no effect on conventional cardiovascular risk factors. A parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab. (in press).

75.

Muldowney S, Lucey AJ, Hill TR, et al. Incremental cholecalciferol supplementation up to 15 μg/d throughout winter at 51-55° N has no effect on biomarkers of cardiovascular risk in healthy young and older adults. J Nutr. 2012;142:1519–25.PubMedCrossRef

76.

Harris SS, Pittas AG, Palermo NJ. A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab. 2012;14:789–94.PubMedCrossRef

77.

• Davidson MB, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. (in press). This randomized controlled trial in a well selected cohort of prediabetic vitamin D deficient patients shows that a high dose vitamin D supplementation does not impact on glucose metabolism or incident diabetes.

78.

Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012;32:195–201.PubMedCrossRef

79.

Beilfuss J, Berg V, Sneve M, et al. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine. (in press).

80.

Carrillo AE, Flynn MG, Pinkston C, et al. Impact of vitamin D supplementation during a resistance training intervention on body composition, muscle function, and glucose tolerance in overweight and obese adults. Clin Nutr. (in press).

81.

de Boer IH, Sachs M, Hoofnagle AN, et al. Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int. In press.

82.

Petchey WG, Hickman IJ, Prins JB, et al. Vitamin D does not improve the metabolic health of patients with Chronic Kidney Disease stage 3-4: a randomized controlled trial. Nephrology. (in press).

83.

Longenecker CT, Hileman CO, Carman TL, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613–21.PubMedCrossRef

84.

Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94:486–94.PubMedCrossRef

85.

Nikooyeh B, Neyestani TR, Farvid M, et al. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. Am J Clin Nutr. 2011;93:764–71.PubMedCrossRef

86.

Shab-Bidar S, Neyestani TR, Djazayery A, et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev. 2012;28:424–30.PubMedCrossRef

87.

Shab-Bidar S, Neyestani TR, Djazayery A, et al. Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial. BMC Med. 2011;9:125.PubMedCrossRef

88.

Mozaffari-Khosravi H, Hosseinzadeh-Shamsi-Anar M, et al. Effects of a single post-partum injection of a high dose of vitamin D on glucose tolerance and insulin resistance in mothers with first-time gestational diabetes mellitus. Diabet Med. 2012;29:36–42.PubMedCrossRef

89.

Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, Hasanzadeh J. Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients. Asia Pac J Clin Nutr. 2011;20:521–6.PubMed

90.

Wehr E, Pilz S, Schweighofer N, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161:575–82.PubMedCrossRef

91.

Lips P. Interaction between vitamin D and calcium. Scand J Clin Lab Invest Suppl. 2012;243:60–4.PubMed

92.

Soares MJ, Murhadi LL, Kurpad AV, et al. Mechanistic roles for calcium and vitamin D in the regulation of body weight. Obes Rev. 2012;13:592–605.PubMedCrossRef

93.

Wagner CL, Greer FR. American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122:1142–52.PubMedCrossRef

94.

Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9.PubMedCrossRef

95.

Hamann C, Kirschner S, Günther KP, Hofbauer LC. Bone, sweet bone–osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8:297–305.PubMedCrossRef

96.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.

97.

Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.PubMedCrossRef

98.

Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.PubMedCrossRef

99.

• Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;7:CD007470. A Cochrane meta-analysis of randomized controlled trials reporting that vitamin D3 supplementation reduces mortality significantly. PubMed

100.

Pilz S, Iodice S, Zittermann A, et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58:374–82.PubMed

101.

Zittermann A, Iodice S, Pilz S, et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012;95:91–100.PubMedCrossRef

102.

Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.PubMed

Title: Role of Vitamin D in the Development of Insulin Resistance and Type 2 Diabetes
Authors: Stefan Pilz
Katharina Kienreich
Femke Rutters
Renate de Jongh
Adriana J. van Ballegooijen
Martin Grübler
Andreas Tomaschitz
Jacqueline M. Dekker
Publication date: 01-04-2013
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 2/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0358-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Diabetes Group Visits: Integrated Medical Care and Behavioral Support to Improve Diabetes Care and Outcomes from a Primary Care Perspective

The Links Between Insulin Resistance, Diabetes, and Cancer

Personalized Decision Support in Type 2 Diabetes Mellitus: Current Evidence and Future Directions

The Role of Community Health Workers in Diabetes: Update on Current Literature

Eating Disorders in Adolescents with Type 2 and Type 1 Diabetes

Circadian Rhythms, Metabolism, and Insulin Sensitivity: Transcriptional Networks in Animal Models

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials